Costs of Integrated Mass Drug Administration for Neglected Tropical Diseases in Haiti
Identifieur interne : 004790 ( Ncbi/Merge ); précédent : 004789; suivant : 004791Costs of Integrated Mass Drug Administration for Neglected Tropical Diseases in Haiti
Auteurs : Ann S. Goldman ; Molly A. Brady ; Abdel Direny ; Luccene Desir ; Roland Oscard ; Jean-Francois Vely ; Mary Linehan ; Margaret BakerSource :
- The American Journal of Tropical Medicine and Hygiene [ 0002-9637 ] ; 2011.
Descripteurs français
- KwdFr :
- Albendazole (administration et posologie), Albendazole (usage thérapeutique), Albendazole (économie), Antihelminthiques (administration et posologie), Antihelminthiques (usage thérapeutique), Antihelminthiques (économie), Coûts et analyse des coûts, Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (usage thérapeutique), Diéthylcarbamazine (économie), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (économie), Filariose lymphatique (épidémiologie), Haïti (épidémiologie), Helminthiase (traitement médicamenteux), Helminthiase (économie), Helminthiase (épidémiologie), Humains, Maladies négligées (traitement médicamenteux), Maladies négligées (économie), Maladies négligées (épidémiologie), Prévalence, Traitement médicamenteux (), Traitement médicamenteux (économie).
- MESH :
- administration et posologie : Albendazole, Antihelminthiques, Diéthylcarbamazine.
- traitement médicamenteux : Filariose lymphatique, Helminthiase, Maladies négligées.
- usage thérapeutique : Albendazole, Antihelminthiques, Diéthylcarbamazine.
- économie : Albendazole, Antihelminthiques, Diéthylcarbamazine, Filariose lymphatique, Helminthiase, Maladies négligées, Traitement médicamenteux.
- épidémiologie : Filariose lymphatique, Haïti, Helminthiase, Maladies négligées.
- Coûts et analyse des coûts, Humains, Prévalence, Traitement médicamenteux.
- Wicri :
- geographic : Haïti.
English descriptors
- KwdEn :
- Albendazole (administration & dosage), Albendazole (economics), Albendazole (therapeutic use), Anthelmintics (administration & dosage), Anthelmintics (economics), Anthelmintics (therapeutic use), Costs and Cost Analysis, Diethylcarbamazine (administration & dosage), Diethylcarbamazine (economics), Diethylcarbamazine (therapeutic use), Drug Therapy (economics), Drug Therapy (methods), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (economics), Elephantiasis, Filarial (epidemiology), Haiti (epidemiology), Helminthiasis (drug therapy), Helminthiasis (economics), Helminthiasis (epidemiology), Humans, Neglected Diseases (drug therapy), Neglected Diseases (economics), Neglected Diseases (epidemiology), Prevalence.
- MESH :
- chemical , administration & dosage : Albendazole, Anthelmintics, Diethylcarbamazine.
- chemical , economics : Albendazole, Anthelmintics, Diethylcarbamazine.
- chemical , therapeutic use : Albendazole, Anthelmintics, Diethylcarbamazine.
- geographic , epidemiology : Haiti.
- drug therapy : Elephantiasis, Filarial, Helminthiasis, Neglected Diseases.
- economics : Drug Therapy, Elephantiasis, Filarial, Helminthiasis, Neglected Diseases.
- epidemiology : Elephantiasis, Filarial, Helminthiasis, Neglected Diseases.
- methods : Drug Therapy.
- Costs and Cost Analysis, Humans, Prevalence.
Abstract
We conducted a cost analysis of Haiti's Ministry of Public Health and Population neglected tropical disease program, Projet des Maladies Tropicales Negligées and collected data for 9 of 55 communes participating in the May 2008–April 2009 mass drug administration (MDA). The Projet des Maladies Tropicales Negligées Program partnered with IMA World Health and Hôpital Ste. Croix to implement MDA for treatment of lymphatic filariasis and soil-transmitted helminthiasis by using once a year treatment with albendazole and diethylcarbamazine in a population of approximately 8 million persons. Methods included analyzing partner financial records and conducting retrospective surveys of personnel. In the nine communes, 633,261 persons were treated at a cost of U.S. $0.64 per person, which included the cost of donated drugs, and at a cost of U.S. $0.42 per person treated, when excluding donated drug costs. The MDA for lymphatic filariasis in Haiti began in 2000, with the treatment of 105,750 persons at a cost per person of U.S. $2.23. The decrease in cost per person treated is the result of cumulative implementation experience and economies of scale.
Url:
DOI: 10.4269/ajtmh.2011.10-0635
PubMed: 22049035
PubMed Central: 3205627
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 002C14
- to stream Pmc, to step Curation: 002C13
- to stream Pmc, to step Checkpoint: 003022
- to stream PubMed, to step Corpus: 002406
- to stream PubMed, to step Curation: 002406
- to stream PubMed, to step Checkpoint: 002406
Links to Exploration step
PMC:3205627Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Costs of Integrated Mass Drug Administration for Neglected Tropical Diseases in Haiti</title>
<author><name sortKey="Goldman, Ann S" sort="Goldman, Ann S" uniqKey="Goldman A" first="Ann S." last="Goldman">Ann S. Goldman</name>
</author>
<author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A." last="Brady">Molly A. Brady</name>
</author>
<author><name sortKey="Direny, Abdel" sort="Direny, Abdel" uniqKey="Direny A" first="Abdel" last="Direny">Abdel Direny</name>
</author>
<author><name sortKey="Desir, Luccene" sort="Desir, Luccene" uniqKey="Desir L" first="Luccene" last="Desir">Luccene Desir</name>
</author>
<author><name sortKey="Oscard, Roland" sort="Oscard, Roland" uniqKey="Oscard R" first="Roland" last="Oscard">Roland Oscard</name>
</author>
<author><name sortKey="Vely, Jean Francois" sort="Vely, Jean Francois" uniqKey="Vely J" first="Jean-Francois" last="Vely">Jean-Francois Vely</name>
</author>
<author><name sortKey="Linehan, Mary" sort="Linehan, Mary" uniqKey="Linehan M" first="Mary" last="Linehan">Mary Linehan</name>
</author>
<author><name sortKey="Baker, Margaret" sort="Baker, Margaret" uniqKey="Baker M" first="Margaret" last="Baker">Margaret Baker</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">22049035</idno>
<idno type="pmc">3205627</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205627</idno>
<idno type="RBID">PMC:3205627</idno>
<idno type="doi">10.4269/ajtmh.2011.10-0635</idno>
<date when="2011">2011</date>
<idno type="wicri:Area/Pmc/Corpus">002C14</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002C14</idno>
<idno type="wicri:Area/Pmc/Curation">002C13</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002C13</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003022</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003022</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">002406</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002406</idno>
<idno type="wicri:Area/PubMed/Curation">002406</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002406</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002406</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002406</idno>
<idno type="wicri:Area/Ncbi/Merge">004790</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Costs of Integrated Mass Drug Administration for Neglected Tropical Diseases in Haiti</title>
<author><name sortKey="Goldman, Ann S" sort="Goldman, Ann S" uniqKey="Goldman A" first="Ann S." last="Goldman">Ann S. Goldman</name>
</author>
<author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A." last="Brady">Molly A. Brady</name>
</author>
<author><name sortKey="Direny, Abdel" sort="Direny, Abdel" uniqKey="Direny A" first="Abdel" last="Direny">Abdel Direny</name>
</author>
<author><name sortKey="Desir, Luccene" sort="Desir, Luccene" uniqKey="Desir L" first="Luccene" last="Desir">Luccene Desir</name>
</author>
<author><name sortKey="Oscard, Roland" sort="Oscard, Roland" uniqKey="Oscard R" first="Roland" last="Oscard">Roland Oscard</name>
</author>
<author><name sortKey="Vely, Jean Francois" sort="Vely, Jean Francois" uniqKey="Vely J" first="Jean-Francois" last="Vely">Jean-Francois Vely</name>
</author>
<author><name sortKey="Linehan, Mary" sort="Linehan, Mary" uniqKey="Linehan M" first="Mary" last="Linehan">Mary Linehan</name>
</author>
<author><name sortKey="Baker, Margaret" sort="Baker, Margaret" uniqKey="Baker M" first="Margaret" last="Baker">Margaret Baker</name>
</author>
</analytic>
<series><title level="j">The American Journal of Tropical Medicine and Hygiene</title>
<idno type="ISSN">0002-9637</idno>
<idno type="eISSN">1476-1645</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (administration & dosage)</term>
<term>Albendazole (economics)</term>
<term>Albendazole (therapeutic use)</term>
<term>Anthelmintics (administration & dosage)</term>
<term>Anthelmintics (economics)</term>
<term>Anthelmintics (therapeutic use)</term>
<term>Costs and Cost Analysis</term>
<term>Diethylcarbamazine (administration & dosage)</term>
<term>Diethylcarbamazine (economics)</term>
<term>Diethylcarbamazine (therapeutic use)</term>
<term>Drug Therapy (economics)</term>
<term>Drug Therapy (methods)</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Elephantiasis, Filarial (economics)</term>
<term>Elephantiasis, Filarial (epidemiology)</term>
<term>Haiti (epidemiology)</term>
<term>Helminthiasis (drug therapy)</term>
<term>Helminthiasis (economics)</term>
<term>Helminthiasis (epidemiology)</term>
<term>Humans</term>
<term>Neglected Diseases (drug therapy)</term>
<term>Neglected Diseases (economics)</term>
<term>Neglected Diseases (epidemiology)</term>
<term>Prevalence</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Albendazole (administration et posologie)</term>
<term>Albendazole (usage thérapeutique)</term>
<term>Albendazole (économie)</term>
<term>Antihelminthiques (administration et posologie)</term>
<term>Antihelminthiques (usage thérapeutique)</term>
<term>Antihelminthiques (économie)</term>
<term>Coûts et analyse des coûts</term>
<term>Diéthylcarbamazine (administration et posologie)</term>
<term>Diéthylcarbamazine (usage thérapeutique)</term>
<term>Diéthylcarbamazine (économie)</term>
<term>Filariose lymphatique (traitement médicamenteux)</term>
<term>Filariose lymphatique (économie)</term>
<term>Filariose lymphatique (épidémiologie)</term>
<term>Haïti (épidémiologie)</term>
<term>Helminthiase (traitement médicamenteux)</term>
<term>Helminthiase (économie)</term>
<term>Helminthiase (épidémiologie)</term>
<term>Humains</term>
<term>Maladies négligées (traitement médicamenteux)</term>
<term>Maladies négligées (économie)</term>
<term>Maladies négligées (épidémiologie)</term>
<term>Prévalence</term>
<term>Traitement médicamenteux ()</term>
<term>Traitement médicamenteux (économie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term>
<term>Anthelmintics</term>
<term>Diethylcarbamazine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Albendazole</term>
<term>Anthelmintics</term>
<term>Diethylcarbamazine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term>
<term>Anthelmintics</term>
<term>Diethylcarbamazine</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Haiti</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term>
<term>Antihelminthiques</term>
<term>Diéthylcarbamazine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term>
<term>Helminthiasis</term>
<term>Neglected Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Drug Therapy</term>
<term>Elephantiasis, Filarial</term>
<term>Helminthiasis</term>
<term>Neglected Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term>
<term>Helminthiasis</term>
<term>Neglected Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term>
<term>Helminthiase</term>
<term>Maladies négligées</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term>
<term>Antihelminthiques</term>
<term>Diéthylcarbamazine</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Albendazole</term>
<term>Antihelminthiques</term>
<term>Diéthylcarbamazine</term>
<term>Filariose lymphatique</term>
<term>Helminthiase</term>
<term>Maladies négligées</term>
<term>Traitement médicamenteux</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term>
<term>Haïti</term>
<term>Helminthiase</term>
<term>Maladies négligées</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Costs and Cost Analysis</term>
<term>Humans</term>
<term>Prevalence</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Coûts et analyse des coûts</term>
<term>Humains</term>
<term>Prévalence</term>
<term>Traitement médicamenteux</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Haïti</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>We conducted a cost analysis of Haiti's Ministry of Public Health and Population neglected tropical disease program, Projet des Maladies Tropicales Negligées and collected data for 9 of 55 communes participating in the May 2008–April 2009 mass drug administration (MDA). The Projet des Maladies Tropicales Negligées Program partnered with IMA World Health and Hôpital Ste. Croix to implement MDA for treatment of lymphatic filariasis and soil-transmitted helminthiasis by using once a year treatment with albendazole and diethylcarbamazine in a population of approximately 8 million persons. Methods included analyzing partner financial records and conducting retrospective surveys of personnel. In the nine communes, 633,261 persons were treated at a cost of U.S. $0.64 per person, which included the cost of donated drugs, and at a cost of U.S. $0.42 per person treated, when excluding donated drug costs. The MDA for lymphatic filariasis in Haiti began in 2000, with the treatment of 105,750 persons at a cost per person of U.S. $2.23. The decrease in cost per person treated is the result of cumulative implementation experience and economies of scale.</p>
</div>
</front>
</TEI>
<double pmid="22049035"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Costs of Integrated Mass Drug Administration for Neglected Tropical Diseases in Haiti</title>
<author><name sortKey="Goldman, Ann S" sort="Goldman, Ann S" uniqKey="Goldman A" first="Ann S." last="Goldman">Ann S. Goldman</name>
</author>
<author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A." last="Brady">Molly A. Brady</name>
</author>
<author><name sortKey="Direny, Abdel" sort="Direny, Abdel" uniqKey="Direny A" first="Abdel" last="Direny">Abdel Direny</name>
</author>
<author><name sortKey="Desir, Luccene" sort="Desir, Luccene" uniqKey="Desir L" first="Luccene" last="Desir">Luccene Desir</name>
</author>
<author><name sortKey="Oscard, Roland" sort="Oscard, Roland" uniqKey="Oscard R" first="Roland" last="Oscard">Roland Oscard</name>
</author>
<author><name sortKey="Vely, Jean Francois" sort="Vely, Jean Francois" uniqKey="Vely J" first="Jean-Francois" last="Vely">Jean-Francois Vely</name>
</author>
<author><name sortKey="Linehan, Mary" sort="Linehan, Mary" uniqKey="Linehan M" first="Mary" last="Linehan">Mary Linehan</name>
</author>
<author><name sortKey="Baker, Margaret" sort="Baker, Margaret" uniqKey="Baker M" first="Margaret" last="Baker">Margaret Baker</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">22049035</idno>
<idno type="pmc">3205627</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205627</idno>
<idno type="RBID">PMC:3205627</idno>
<idno type="doi">10.4269/ajtmh.2011.10-0635</idno>
<date when="2011">2011</date>
<idno type="wicri:Area/Pmc/Corpus">002C14</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002C14</idno>
<idno type="wicri:Area/Pmc/Curation">002C13</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002C13</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003022</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003022</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Costs of Integrated Mass Drug Administration for Neglected Tropical Diseases in Haiti</title>
<author><name sortKey="Goldman, Ann S" sort="Goldman, Ann S" uniqKey="Goldman A" first="Ann S." last="Goldman">Ann S. Goldman</name>
</author>
<author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A." last="Brady">Molly A. Brady</name>
</author>
<author><name sortKey="Direny, Abdel" sort="Direny, Abdel" uniqKey="Direny A" first="Abdel" last="Direny">Abdel Direny</name>
</author>
<author><name sortKey="Desir, Luccene" sort="Desir, Luccene" uniqKey="Desir L" first="Luccene" last="Desir">Luccene Desir</name>
</author>
<author><name sortKey="Oscard, Roland" sort="Oscard, Roland" uniqKey="Oscard R" first="Roland" last="Oscard">Roland Oscard</name>
</author>
<author><name sortKey="Vely, Jean Francois" sort="Vely, Jean Francois" uniqKey="Vely J" first="Jean-Francois" last="Vely">Jean-Francois Vely</name>
</author>
<author><name sortKey="Linehan, Mary" sort="Linehan, Mary" uniqKey="Linehan M" first="Mary" last="Linehan">Mary Linehan</name>
</author>
<author><name sortKey="Baker, Margaret" sort="Baker, Margaret" uniqKey="Baker M" first="Margaret" last="Baker">Margaret Baker</name>
</author>
</analytic>
<series><title level="j">The American Journal of Tropical Medicine and Hygiene</title>
<idno type="ISSN">0002-9637</idno>
<idno type="eISSN">1476-1645</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>We conducted a cost analysis of Haiti's Ministry of Public Health and Population neglected tropical disease program, Projet des Maladies Tropicales Negligées and collected data for 9 of 55 communes participating in the May 2008–April 2009 mass drug administration (MDA). The Projet des Maladies Tropicales Negligées Program partnered with IMA World Health and Hôpital Ste. Croix to implement MDA for treatment of lymphatic filariasis and soil-transmitted helminthiasis by using once a year treatment with albendazole and diethylcarbamazine in a population of approximately 8 million persons. Methods included analyzing partner financial records and conducting retrospective surveys of personnel. In the nine communes, 633,261 persons were treated at a cost of U.S. $0.64 per person, which included the cost of donated drugs, and at a cost of U.S. $0.42 per person treated, when excluding donated drug costs. The MDA for lymphatic filariasis in Haiti began in 2000, with the treatment of 105,750 persons at a cost per person of U.S. $2.23. The decrease in cost per person treated is the result of cumulative implementation experience and economies of scale.</p>
</div>
</front>
</TEI>
</pmc>
<pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Costs of integrated mass drug administration for neglected tropical diseases in Haiti.</title>
<author><name sortKey="Goldman, Ann S" sort="Goldman, Ann S" uniqKey="Goldman A" first="Ann S" last="Goldman">Ann S. Goldman</name>
<affiliation wicri:level="1"><nlm:affiliation>The George Washington University School of Public Health and Health Services, Washington, District of Columbia 20037, USA. sphasg@gwumc.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The George Washington University School of Public Health and Health Services, Washington, District of Columbia 20037</wicri:regionArea>
<wicri:noRegion>District of Columbia 20037</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A" last="Brady">Molly A. Brady</name>
</author>
<author><name sortKey="Direny, Abdel" sort="Direny, Abdel" uniqKey="Direny A" first="Abdel" last="Direny">Abdel Direny</name>
</author>
<author><name sortKey="Desir, Luccene" sort="Desir, Luccene" uniqKey="Desir L" first="Luccene" last="Desir">Luccene Desir</name>
</author>
<author><name sortKey="Oscard, Roland" sort="Oscard, Roland" uniqKey="Oscard R" first="Roland" last="Oscard">Roland Oscard</name>
</author>
<author><name sortKey="Vely, Jean Francois" sort="Vely, Jean Francois" uniqKey="Vely J" first="Jean-Francois" last="Vely">Jean-Francois Vely</name>
</author>
<author><name sortKey="Linehan, Mary" sort="Linehan, Mary" uniqKey="Linehan M" first="Mary" last="Linehan">Mary Linehan</name>
</author>
<author><name sortKey="Baker, Margaret" sort="Baker, Margaret" uniqKey="Baker M" first="Margaret" last="Baker">Margaret Baker</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:22049035</idno>
<idno type="pmid">22049035</idno>
<idno type="doi">10.4269/ajtmh.2011.10-0635</idno>
<idno type="wicri:Area/PubMed/Corpus">002406</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002406</idno>
<idno type="wicri:Area/PubMed/Curation">002406</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002406</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002406</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002406</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Costs of integrated mass drug administration for neglected tropical diseases in Haiti.</title>
<author><name sortKey="Goldman, Ann S" sort="Goldman, Ann S" uniqKey="Goldman A" first="Ann S" last="Goldman">Ann S. Goldman</name>
<affiliation wicri:level="1"><nlm:affiliation>The George Washington University School of Public Health and Health Services, Washington, District of Columbia 20037, USA. sphasg@gwumc.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The George Washington University School of Public Health and Health Services, Washington, District of Columbia 20037</wicri:regionArea>
<wicri:noRegion>District of Columbia 20037</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brady, Molly A" sort="Brady, Molly A" uniqKey="Brady M" first="Molly A" last="Brady">Molly A. Brady</name>
</author>
<author><name sortKey="Direny, Abdel" sort="Direny, Abdel" uniqKey="Direny A" first="Abdel" last="Direny">Abdel Direny</name>
</author>
<author><name sortKey="Desir, Luccene" sort="Desir, Luccene" uniqKey="Desir L" first="Luccene" last="Desir">Luccene Desir</name>
</author>
<author><name sortKey="Oscard, Roland" sort="Oscard, Roland" uniqKey="Oscard R" first="Roland" last="Oscard">Roland Oscard</name>
</author>
<author><name sortKey="Vely, Jean Francois" sort="Vely, Jean Francois" uniqKey="Vely J" first="Jean-Francois" last="Vely">Jean-Francois Vely</name>
</author>
<author><name sortKey="Linehan, Mary" sort="Linehan, Mary" uniqKey="Linehan M" first="Mary" last="Linehan">Mary Linehan</name>
</author>
<author><name sortKey="Baker, Margaret" sort="Baker, Margaret" uniqKey="Baker M" first="Margaret" last="Baker">Margaret Baker</name>
</author>
</analytic>
<series><title level="j">The American journal of tropical medicine and hygiene</title>
<idno type="eISSN">1476-1645</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (administration & dosage)</term>
<term>Albendazole (economics)</term>
<term>Albendazole (therapeutic use)</term>
<term>Anthelmintics (administration & dosage)</term>
<term>Anthelmintics (economics)</term>
<term>Anthelmintics (therapeutic use)</term>
<term>Costs and Cost Analysis</term>
<term>Diethylcarbamazine (administration & dosage)</term>
<term>Diethylcarbamazine (economics)</term>
<term>Diethylcarbamazine (therapeutic use)</term>
<term>Drug Therapy (economics)</term>
<term>Drug Therapy (methods)</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Elephantiasis, Filarial (economics)</term>
<term>Elephantiasis, Filarial (epidemiology)</term>
<term>Haiti (epidemiology)</term>
<term>Helminthiasis (drug therapy)</term>
<term>Helminthiasis (economics)</term>
<term>Helminthiasis (epidemiology)</term>
<term>Humans</term>
<term>Neglected Diseases (drug therapy)</term>
<term>Neglected Diseases (economics)</term>
<term>Neglected Diseases (epidemiology)</term>
<term>Prevalence</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Albendazole (administration et posologie)</term>
<term>Albendazole (usage thérapeutique)</term>
<term>Albendazole (économie)</term>
<term>Antihelminthiques (administration et posologie)</term>
<term>Antihelminthiques (usage thérapeutique)</term>
<term>Antihelminthiques (économie)</term>
<term>Coûts et analyse des coûts</term>
<term>Diéthylcarbamazine (administration et posologie)</term>
<term>Diéthylcarbamazine (usage thérapeutique)</term>
<term>Diéthylcarbamazine (économie)</term>
<term>Filariose lymphatique (traitement médicamenteux)</term>
<term>Filariose lymphatique (économie)</term>
<term>Filariose lymphatique (épidémiologie)</term>
<term>Haïti (épidémiologie)</term>
<term>Helminthiase (traitement médicamenteux)</term>
<term>Helminthiase (économie)</term>
<term>Helminthiase (épidémiologie)</term>
<term>Humains</term>
<term>Maladies négligées (traitement médicamenteux)</term>
<term>Maladies négligées (économie)</term>
<term>Maladies négligées (épidémiologie)</term>
<term>Prévalence</term>
<term>Traitement médicamenteux ()</term>
<term>Traitement médicamenteux (économie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term>
<term>Anthelmintics</term>
<term>Diethylcarbamazine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Albendazole</term>
<term>Anthelmintics</term>
<term>Diethylcarbamazine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term>
<term>Anthelmintics</term>
<term>Diethylcarbamazine</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Haiti</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term>
<term>Antihelminthiques</term>
<term>Diéthylcarbamazine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term>
<term>Helminthiasis</term>
<term>Neglected Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Drug Therapy</term>
<term>Elephantiasis, Filarial</term>
<term>Helminthiasis</term>
<term>Neglected Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term>
<term>Helminthiasis</term>
<term>Neglected Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term>
<term>Helminthiase</term>
<term>Maladies négligées</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term>
<term>Antihelminthiques</term>
<term>Diéthylcarbamazine</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Albendazole</term>
<term>Antihelminthiques</term>
<term>Diéthylcarbamazine</term>
<term>Filariose lymphatique</term>
<term>Helminthiase</term>
<term>Maladies négligées</term>
<term>Traitement médicamenteux</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term>
<term>Haïti</term>
<term>Helminthiase</term>
<term>Maladies négligées</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Costs and Cost Analysis</term>
<term>Humans</term>
<term>Prevalence</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Coûts et analyse des coûts</term>
<term>Humains</term>
<term>Prévalence</term>
<term>Traitement médicamenteux</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Haïti</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We conducted a cost analysis of Haiti's Ministry of Public Health and Population neglected tropical disease program, Projet des Maladies Tropicales Negligées and collected data for 9 of 55 communes participating in the May 2008-April 2009 mass drug administration (MDA). The Projet des Maladies Tropicales Negligées Program partnered with IMA World Health and Hôpital Ste. Croix to implement MDA for treatment of lymphatic filariasis and soil-transmitted helminthiasis by using once a year treatment with albendazole and diethylcarbamazine in a population of approximately 8 million persons. Methods included analyzing partner financial records and conducting retrospective surveys of personnel. In the nine communes, 633,261 persons were treated at a cost of U.S. $0.64 per person, which included the cost of donated drugs, and at a cost of U.S. $0.42 per person treated, when excluding donated drug costs. The MDA for lymphatic filariasis in Haiti began in 2000, with the treatment of 105,750 persons at a cost per person of U.S. $2.23. The decrease in cost per person treated is the result of cumulative implementation experience and economies of scale.</div>
</front>
</TEI>
</pubmed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004790 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004790 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= PMC:3205627 |texte= Costs of Integrated Mass Drug Administration for Neglected Tropical Diseases in Haiti }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22049035" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |